Cost-effectiveness of different human papillomavirus vaccines in Singapore

BMC Public Health

Volumn 11, Issue , 2011, Pages

  Lee, Vernon J ^a   Tay, Sun Kuie ^b   Teoh, Yee Leong ^c   Tok, Mei Yin ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c GLAXOSMITHKLINE   (Singapore)

Author keywords

Cervical cancer; cervical intraepithelial neoplasia; incremental cost effectiveness ratio; vaccine

Indexed keywords

HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18; WART VIRUS VACCINE;

ARTICLE; CHILD; COMPARATIVE STUDY; CONDYLOMA ACUMINATUM; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; FOLLOW UP; HUMAN; METHODOLOGY; PAPILLOMAVIRUS INFECTION; QUALITY ADJUSTED LIFE YEAR; SINGAPORE; UTERINE CERVIX TUMOR; VACCINATION;

CHILD; CONDYLOMATA ACUMINATA; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; SINGAPORE; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 79955601012     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-203     Document Type: Article

References (51)

1. Golbal cancer statistics, 2002. DM Parkin F Bray J Ferlay P Pisani, CA Cancer J Clin 2005 55 74 108 10.3322/canjclin.55.2.74 15761078
2. th July 2009]
3. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan. SK Tay HY Ngan TY Chu AN Cheung EH Tay, Vaccine 2008 26 Suppl 12 60 70 10.1016/j.vaccine.2008.05.042 18945415
4. th July 2009]
5. Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Munoz FX Boasch S de Sanjose,, et al. N Engl J Med 2003 348 518 27 10.1056/NEJMoa021641 12571259 (Pubitemid 36159887)
6. Human papillomavirus and cervical cancer. EM Burd, Clin Microbiol Rev 2003 16 1 17 10.1128/CMR.16.1.1-17.2003 12525422 (Pubitemid 36114705)
7. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. GM Clifford JS Smith T Aguado,, et al. Br J Cancer 2003 89 101 5 10.1038/sj.bjc.6601024 12838308 (Pubitemid 36897943)
8. Cost-effectiveness of HPV vaccination compared with PAP smear screening on a national scale: a literature review. W Techakehakij RD Feldman, Vaccine 2008 26 49 6258 6265 10.1016/j.vaccine.2008.09.036 18835313
9. Cost-effectiveness of human papillomavirus vaccination in the United States. HW Chesson DU Ekwueme M Saraiya LE Markowtiz, Emerg Infect Dis 2008 14 244 51 10.3201/eid1402.070499 18258117 (Pubitemid 351213674)
10. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. SJ Goldie M Kohli D Grima,, et al. J Natl Cancer Inst 2004 96 8 604 615 10.1093/jnci/djh104 15100338 (Pubitemid 38584984)
11. Health and economic implications of HPV vaccination in the United States. JJ Kim SJ Goldie, New England Journal of Medicine 2008 359 8 821 832 10.1056/NEJMsa0707052 18716299
12. Potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. M Brisson N Van de Valde P De Wals MC Boily, Vaccine 2007 25 29 5399 408 10.1016/j.vaccine.2007.04.086 17561316 (Pubitemid 46977529)
13. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. SL Kulasingam S Benard RV Barnabas N Largeron ER Myers, Cost Effectiveness and Resource Allocation 2008 6 4 10.1186/1478-7547-6-4 18279515
14. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. EJ Dasbach RP Insinga EH Elbasha, BJOG: an International Journal of Obstetrics and Gynaecology 2008 115 8 947 956 10.1111/j.1471-0528.2008.01743.x 18503574 (Pubitemid 351841762)
15. Economic evaluation of human papillomavirus vaccination in the United Kingdom. M Jit YH Choi WJ Edmunds, BMJ 2008 337 769 10.1136/bmj.a769 18640957
16. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. TD Szucs N Largeron KJ Dedes R Rafia S Benard, Curr Med Res Opin 2008 24 5 1473 83 May 10.1185/ 030079908X297826 18413014 (Pubitemid 351741581)
17. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. JJ Kim KE Kobus M Diaz,, et al. Vaccine 2008 26 32 4015 4024 10.1016/j.vaccine.2008.05.038 18602731
18. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. EJ Dasbach EH Elbasha RP Insinga, Epidemiol Rev 2006 28 99 100 10.1093/epirev/mxj006 (Pubitemid 44289092)
19. Model of assessing human papillomavirus vaccination strategies. EH Elbasha EJ Dasbach RP Insinga, Emerg Infect Dis 2007 13 1 28 41 10.3201/eid1301.060438 17370513 (Pubitemid 46057835)
20. Singapore Department of Statistics, Complete Life Tables 2006-2008 for Singapore Resident Population http://www.singstat.gov.sg/pubn/popn/lifetable06- 09.pdf [online]. [Accessed 15th April 2011]
21. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. M Kohli N Ferko A Martin EL Franco D Jenkins S Gallivan,, et al. Br J Cancer 2007 96 1 143 50 10.1038/sj.bjc.6603501 17146475 (Pubitemid 46094653)
22. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian. S Kulasingam L Connelly E Conway JS Hocking E Myers DG Regan D Roder J Ross G Wain, National Cervical Cancer Screening Program. Sexual Health 2007 4 165 175 (Pubitemid 47339645)
23. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. J Paavonen P Naup J Salmeon CM Wheeler SN Chow D Apter,, et al. Lancet 2009 374 9686 301 314 10.1016/S0140-6736(09)61248-4 19586656
24. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. RM Rogoza N Ferko J Bentley,, et al. Vaccine 2008 26S 46 F58 10.1016/j.vaccine.2008.02.039
25. Comparison of detailed and succinct cohort modeling approaches in the evaluation of cervical cancer vaccination. D Debicki N Ferko N Demarteau S Gallivan CT Bauch A Anonychuk,, et al. Vaccine 2008 26S 16 F28 10.1016/j.vaccine.2008.02.040
26. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. E Surez JS Smith FX Bosch,, et al. Vaccine 2008 26S 29 F45
27. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. FUTURE I/II Study Group, BMJ 2010 341 3493 10.1136/bmj.c3493 20647284
28. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. LL Villa RL Costa CA Petta RP Andrade J Paavonen OE Iversen,, et al. Br J Cancer 2006 95 11 1459 66 10.1038/sj.bjc.6603469 17117182 (Pubitemid 44863348)
29. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. A Dee F Howell, Eur J Public Health 2010 20 2 213 9 10.1093/eurpub/ckp141 19864366
30. Human papillomavirus testing in primary cervical screening. J Cuzick A Szarewski G Terry L Ho,, et al. Lancet 1995 345 8964 1533 6 10.1016/S0140- 6736(95)91086-7 7791438
31. Meta-analysis of Pap test accuracy. MT Fahey L Irwig P Macaskill, Am J Epidemiol 1995 141 7 680 689 7702044
32. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. DR Brown SK Kjaer K Sigurdsson OE Iversen,, et al. J Infect Dis 2009 199 7 926 35 10.1086/597307 19236279
33. Cross-protective efficacy of The bivalent vaccine against oncogenic HPV types beyond HPV-16/18. SR Skinner,, et al. Abstract presented at the 25th International Papillomavirus Conference (IPV) Malmo, Sweden 2009
34. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. DR Brown KH Fife CM Wheeler LA Koutsky,, et al. Vaccine 2004 22 21-22 2936 42 10.1016/j.vaccine.2003.11.059 15246630 (Pubitemid 38900673)
35. Sustained efficacy up to 4.5 years of a bivalent L1-virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized controlled trial. DM Harper EL Franco CM Wheeler AB Moscicki B Romanowski CM Roteli-Martins,, et al. Lancet 2006 367 9518 1247 55 10.1016/S0140-6736(06)68439-0 16631880
36. A controlled trial of human papillomavirus type 16 vaccine. LA Koutsky KA Ault CM Wheeler DR Brown E Barr FB Alvarez,, et al. N Engl J Med 2002 347 21 1645 51 10.1056/NEJMoa020586 12444178 (Pubitemid 35340782)
37. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. C Mao LA Koutsky KA Ault CM Wheeler DR Brown DJ Wiley,, et al. Obstet Gynecol 2006 107 1 18 27 10.1097/01.AOG.0000192397.41191.fb 16394035
38. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. LL Villa KA Ault AR Giuliano RL Costa CA Petta RP Andrade,, et al. Vaccine 2006 24 27-28 5571 83 10.1016/j.vaccine.2006.04.068 16753240 (Pubitemid 44172918)
39. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with HPV types 16 and 18 in young women: an interim analysis of a phase III double-blind randomized controlled trial. J Paavonen D Jenkins X Bosch P Naud J Salmeron CM Wheeler, Lancet 2007 369 9580 2161 70 10.1016/S0140-6736(07)60946-5 17602732 (Pubitemid 46977438)
40. Quadrivalent vaccine against HPV to prevent highgrade lesions. The FUTURE II Study Group, N Engl J Med 2007 356 19 1915 27 10.1056/NEJMoa061741 17494925
41. Abnormal Pap Smear & Preinvasive Disease of the Cervix. Health Promotion Board, Health Promotion Board, Singapore 2002
42. Population-based survival for cervical cancer in Singapore, 1968-1992. H Wang KS Chia WB Du,, et al. Am J Obstet Gynecol 2003 188 324 9 10.1067/mob.2003.89 12592234 (Pubitemid 36249965)
43. European course on HPV associated pathology: guidelines for primary case physicians for the diagnosis and management of anogenital warts. G Von Krogh CJ Lacey G Gross,, et al. Sex Transm Infect 2000 76 162 8 10.1136/sti.76.3.162 10961190 (Pubitemid 30435195)
44. What can surveillance of genital warts tell us? CK Fairley B Donovan, Sex Health 2010 7 3 325 7 10.1071/SH09145 20719222
45. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. SJ Goldie M Kohli D Grima,, et al. J Natl Cancer Inst 2004 96 8 604 615 10.1093/jnci/djh104 15100338 (Pubitemid 38584984)
46. Methodological Issues in Conducting Pharmacoeconomic Evaluations - Modeling Studies. J Hay J Jackson, Value in Health 1999 2 No. 3 78 81 10.1046/j.1524-4733.1999.02203.x 16674337
47. The discount rate in the economic evaluation of prevention: a thought experiment. L Bonneux E Birnie, J Epidemiol Community Health 2001 55 2 123 5 10.1136/jech.55.2.123 11154251 (Pubitemid 32095198)
48. Disconting health effects in pharmacoeconomic evaluations: current controversies. JM Bos MJ Postma L Annemans, Pharmacoeconomics 2005 23 7 639 49 10.2165/00019053-200523070-00001 16173156 (Pubitemid 41003073)
49. Economic notes. Discounting. DJ Torgenson L Raftery, BMJ 1999 319 7214 914 5 10506056
50. Prevention Effectiveness- A Guide to Decision Analysis and Economic Evaluation. AC Haddix SM Teutsh PS Corso, New York: Oxford University Press 2 2003 18
51. Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan. PH Liu FC Hu PI Lee SN Chow CW Huang JD Wang, BMC Health Serv Res 2010 10 11 10.1186/1472-6963-10-11 20064239